A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR Amyloidosis

Trial Profile

A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR Amyloidosis

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Patisiran (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Adverse reactions
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 21 Mar 2014 Results from a further analyses of trial data will be presented at the XIVth International Symposium on Amyloidosis (ISA) according to an Alnylam Pharmaceuticals media release.
    • 22 Nov 2013 New trial record
    • 10 Nov 2013 Results published in an Alnylam Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top